The treatment of three yin breast cancer has been breakthrough

The research team photo Xiao Ying photo
December 11, reporters from Sun Yat-sen University Cancer Prevention and Control Center was informed that the center professor Yuan Zhongyu, Wang Wei, Wang Shusen and other breast cancer team completed the "surgical three-negative breast cancer standard treatment after the Caperthabin beat maintenance phase III clinical research (SYSUCC-001)" recently published in the form of original research in the Journal of the American Medical Association.
the study is the first large-scale Phase III. clinical trial in the world to use beat chemotherapy for maintenance treatment after standard treatment for early triple-negative breast cancer and to achieve positive results. Yuan Zhongyu is the author of this paper, Wang Wei and Wang Shusen are the co-first authors.
cancer is the world's highest incidence of malignant tumors, and morbidity and mortality rate is increasing year by year. Chemotherapy is the main means to reduce the risk of recurrence of early tri-negative breast cancer, but the efficacy has reached a bottleneck. Clinically, more effective means are urgently needed to further improve the cure rate of early triple negative breast cancer.
Kapethamin is a classic chemotherapy drug that has been used clinically for many years, and its low-dose, high-frequency, continuous oral "beat-type" dosing method has good effectiveness and safety in advanced tumors. For patients with early tricyctic breast cancer, the efficacy of standard chemotherapy has reached a bottleneck, so after the end of standard chemotherapy to continue to use Capedabin "beat chemotherapy" as maintenance treatment can reduce the risk of recurrence?
, the researchers conducted the multi-center, randomized controlled study in 2010. After ten years of joint efforts by 13 domestic cooperative units, the study was successfully completed this year and achieved encouraging results: Capentabin beat chemotherapy as a maintenance treatment, reducing the risk of recurrence of early triple negative breast cancer by more than 1/3, and increasing the patient's five-year disease-free survival rate from 73.0% to 82.8%.
Yuan Zhongyu, the safety of beat chemotherapy is good, 83% of patients can successfully complete the whole treatment without serious toxic side effects. It is worth mentioning that the total cost of maintenance treatment in Kapethabin for a year is less than 4000 yuan, after reimbursement of patients only need to bear about 1000 yuan, its cost-effective and popularity is self-evident. (Source: China Science Journal Zhu Hanbin Chen Wei)
relevant paper information: